NRP388

NRP388 is a monoclonal antibody designed to target Neuropilin-1 (NRP1), a transmembrane glycoprotein that acts as a co-receptor for various ligands, including vascular endothelial growth factor (VEGF) and semaphorins. By binding to NRP1, NRP388 aims to inhibit the signaling pathways involved in angiogenesis, tumor cell survival, and immune evasion. The drug is primarily being investigated for its potential in treating various solid tumors, where NRP1 is often overexpressed and contributes to disease progression and resistance to standard therapies. NRP388 is developed by NRP Therapeutics, focusing on the role of neuropilins in the tumor microenvironment and their potential as therapeutic targets in oncology.